August 31, 2007, Outcome Capital announced the completion of a “significant” recapitalization of Preferred Systems Solutions (PSS), Inc., a leader in providing Information Technology, Engineering, Logistics Management Support and Consulting Services, by an investment group led by CM Equity Partners, LLC. Outcome Capital acted as financial advisor to PSS on this transaction. Founder and CEO Robert Hisel commented, “Our team is very excited by both our new partnership with CMEP, who is well respected as a successful financial investor in our market, and our closer relationship with Scott Goss who is well known in our industry as an accomplished leader.” Peter Schulte, a partner with CMEP commented, “We are looking forward to working closely with Rob and Scott, whom we have known well for some time, to help support the continued growth of the company.” Scott Goss, the newly appointed CEO commented, “PSS’s dedication and commitment to their customers and employees are truly remarkable. It’s an exciting, entrepreneurial company with extremely high integrity. I am thrilled to become a member of PSS and am dedicated to building upon the company’s culture of customer responsiveness, employee development, excellence and integrity.”
About PSS
PSS is a privately held firm that provides IT services, engineering, and program management support services both directly and indirectly to various agencies of the U.S. Federal Government. Major clients include the U.S. Army, U.S. Navy, the Defense Logistics Agency, and Department of Homeland Security. The company has approximately 300 employees and is headquartered in McLean, VA.
About CM Equity Partners
CM Equity Partners is a private equity investment firm which makes controlling investments in middle-market companies operating primarily in the U.S. and Canada. Since 1993, CMEP has completed more than 40 acquisitions, with more than half being in the Federal services sector. CMEP’s investments in this sector include AverStar, Inc., Resource Consultants, Inc., RGS Associates, Inc., ICF International, Inc. (Nasdaq: ICFI – News), and 3001 International, Inc., among others.
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read More
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?